Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

7.90USD
22 Jun 2018
Change (% chg)

$0.06 (+0.77%)
Prev Close
$7.84
Open
$7.81
Day's High
$7.96
Day's Low
$7.70
Volume
11,434
Avg. Vol
19,108
52-wk High
$11.24
52-wk Low
$4.30

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  RDHL.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -- -- --
ROI: -- 2.00 14.38
ROE: -- 3.49 16.08

BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share

* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial

* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE

May 07 2018

BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia

* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIA® FOR H. PYLORI INFECTION

May 04 2018

BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg

* PLANS TO MEET WITH FDA IN Q2 OF 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:

Apr 09 2018

BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis

* REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA® 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING

Mar 27 2018

BRIEF-Redhill Biopharma Q4 Basic Loss Per Ordinary Share $0.05

* CASH BALANCE AS OF DECEMBER 31, 2017 WAS $46.2 MILLION, A DECREASE OF $20 MILLION, COMPARED TO $66.2 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D

* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDA® FOR IBS-D

Jan 16 2018

Earnings vs. Estimates

No consensus analysis data available.